welcome
therapeutics to improve cardiovascular health
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA approved product and is available in the United States by prescription. For more information about Vascepa visit www.vascepa.com.
recent news
12 Sep 2018
REDUCE-IT™ Trial Primary Results Accepted for Presentation at 2018 Scientific Sessions of American Heart Association MORE
26 Aug 2018
Amarin’s REDUCE-IT™ Clinical Study Now Positioned to be Next Large Cardiovascular Outcomes Study to Report Results MORE
Stock Information
- Symbol:
- AMRN (NASDAQ)
- Quote:
- $2.83
- Change:
- -0.07
- Date:
- 4:00 PM EDT on Sep 17, 2018
Join Our Mailing List
You may automatically receive Amarin Corporation plc financial information by email.